Emerald Advisers’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-4
Closed -$3K 293
2020
Q3
$3K Hold
4
﹤0.01% 330
2020
Q2
$3K Buy
+4
New +$3.02K ﹤0.01% 312
2020
Q1
Sell
-4
Closed -$4K 223
2019
Q4
$4K Buy
+4
New +$4.35K ﹤0.01% 333
2018
Q2
Sell
-2,240
Closed -$4.96M 253
2018
Q1
$4.96M Sell
2,240
-4,360
-66% -$11.1M 0.2% 117
2017
Q4
$15.2M Sell
6,600
-7,567
-53% -$15.4M 0.59% 67
2017
Q3
$25.2M Sell
14,167
-978
-6% -$1.37M 1.03% 34
2017
Q2
$20.6M Buy
15,145
+10,212
+207% +$12.3M 0.86% 53
2017
Q1
$5.81M Sell
4,933
-7,800
-61% -$7.96M 0.24% 108
2016
Q4
$10.2M Sell
12,733
-16,105
-56% -$12.8M 0.43% 87
2016
Q3
$25.3M Buy
28,838
+13,850
+92% +$10M 1.13% 20
2016
Q2
$8.4M Sell
14,988
-5,152
-26% -$2.92M 0.4% 89
2016
Q1
$11.1M Buy
20,140
+2,365
+13% +$1.45M 0.54% 68
2015
Q4
$14.8M Buy
17,775
+12,389
+230% +$12.4M 0.7% 47
2015
Q3
$5.97M Buy
5,386
+679
+14% +$1.24M 0.31% 108
2015
Q2
$10.3M Sell
4,707
-1,664
-26% -$3.39M 0.49% 72
2015
Q1
$11M Sell
6,371
-10,539
-62% -$13.9M 0.55% 60
2014
Q4
$20.1M Sell
16,910
-3,733
-18% -$2.49M 1.07% 19
2014
Q3
$9.59M Buy
+20,643
New +$9.53M 0.57% 52

Other funds holding BLUE

Emerald Advisers's BLUE Position: Q4 2020 in Review

Emerald Advisers sold out of bluebird bio (BLUE) in Q4 2020, closing a stake of 4 shares — an estimated $3K sold.

Emerald Advisers first reported a position in BLUE in Q3 2014 and held it in 18 quarters. The position peaked at $25.3M in Q3 2016. 262 funds tracked by Wall St. Rank hold BLUE as of Q4 2020.

  • Emerald Advisers reported no remaining bluebird bio position as of Q4 2020 after selling out during the quarter.
  • Emerald Advisers sold 4 bluebird bio shares in Q4 2020, an estimated $3K.
  • Emerald Advisers first reported a position in bluebird bio in Q3 2014 and held it in 18 quarters.
  • Emerald Advisers's bluebird bio position peaked at $25.3M in Q3 2016.
  • 262 funds tracked by Wall St. Rank held bluebird bio as of Q4 2020.

Based on Emerald Advisers's 13F filing for Q4 2020, filed 29 Jan 2021.